This HTML5 document contains 50 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n12http://linked.opendata.cz/resource/drugbank/drug/DB06717/identifier/kegg-drug/
n2http://linked.opendata.cz/resource/drugbank/drug/
n14http://linked.opendata.cz/resource/drugbank/drug/DB06717/identifier/drugbank/
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/AHFS/
n9http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB06717/identifier/wikipedia/
n10http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n15http://linked.opendata.cz/resource/drugbank/drug/DB06717/identifier/pharmgkb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n13http://linked.opendata.cz/resource/drugbank/drug/DB06717/identifier/pubchem-compound/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB06717/identifier/pubchem-substance/
n5http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB06717
rdf:type
n3:Drug
n3:description
Fosaprepitant is an intravenously administered antiemetic drug. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment.
n3:group
approved
n3:halfLife
9-13 hours
n3:indication
For the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy.
owl:sameAs
n9:DB06717 n10:DB06717
dcterms:title
Fosaprepitant
adms:identifier
n12:D06597 n13:219090 n14:DB06717 n15:PA165958390 n16:Fosaprepitant n17:99443269
n3:mechanismOfAction
Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with Aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies show that Aprepitant augments the antiemetic activity of the 5-HT<sub>3</sub>-receptor antagonist ondansetron and the corticosteroid ethasone and inhibits both the acute and delayed phases of cisplatin induced emesis. In summary, the active form of fosaprepitant is as an NK1 antagonist which is because it blocks signals given off by NK1 receptors. This therefore decreases the likelihood of vomiting in patients experiencing.
n3:routeOfElimination
Aprepitant is eliminated primarily by metabolism; aprepitant is not renally excreted. Aprepitant is excreted in the milk of rats. It is not known whether this drug is excreted in human milk.
n3:synonym
L-758298 Fosaprepitantum L-758,298
n5:hasAHFSCode
n6:56-22-92
n3:proteinBinding
95% +
n3:salt
n3:synthesisReference
Navin Ganesh Bhatt, Nikhil Rasiklal Trivedi, Mahesh Khedekar, Sukumar Sinha, Mubeen Ahmed Khan, Ramjilal Yadav, "FOSAPREPITANT DIMEGLUMINE INTERMEDIATE, NEUTRAL FOSAPREPITANT, AND AMORPHOUS FOSAPREPITANT DIMEGLUMINE AND PROCESSES FOR THEIR PREPARATIONS." U.S. Patent US20110130366, issued June 02, 2011.
n3:IUPAC-Name
n4:271B511D-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5123-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5122-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B511F-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5120-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5121-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B511B-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B511C-363D-11E5-9242-09173F13E4C5 n4:271B5119-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B511A-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5129-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B512A-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5124-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5125-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5127-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5126-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5128-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
172673-20-0
n3:Bioavailability
n4:271B512F-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5131-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5132-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B512E-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B512D-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5130-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B511E-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B512B-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B512C-363D-11E5-9242-09173F13E4C5